Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer

BACKGROUND: Targeted therapies for triple-negative breast cancer (TNBC) are limited; however, the epidermal growth factor receptor (EGFR) represents a potential target, as the majority of TNBC express EGFR. The purpose of these studies was to evaluate the effectiveness of two EGFR-targeted antibody-...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Breast Cancer Res
Hauptverfasser: Zoeller, Jason J., Vagodny, Aleksandr, Daniels, Veerle W., Taneja, Krishan, Tan, Benjamin Y., DeRose, Yoko S., Fujita, Maihi, Welm, Alana L., Letai, Anthony, Leverson, Joel D., Blot, Vincent, Bronson, Roderick T., Dillon, Deborah A., Brugge, Joan S.
Format: Artigo
Sprache:Inglês
Veröffentlicht: BioMed Central 2020
Schlagworte:
Research Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7708921/
https://ncbi.nlm.nih.gov/pubmed/33256808
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13058-020-01374-8
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge